KLISYRI

This brand name is authorized in Estonia, Spain, France, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug KLISYRI contains one active pharmaceutical ingredient (API):

1 Tirbanibulin UNII 4V9848RS5G - TIRBANIBULIN

Tirbanibulin disrupts microtubules by direct binding to tubulin, which induces cell cycle arrest and apoptotic death of proliferating cells, and is associated with disruption of Src tyrosine kinase signalling. Read about Tirbanibulin

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
KLISYRI Ointment	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
D06BX03		D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BX Other chemotherapeutics
Discover more medicines within D06BX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 1858080
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 1211558001
Country: FR	Base de données publique des médicaments	Identifier(s): 62644226
Country: IT	Agenzia del Farmaco	Identifier(s): 049607017
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1092973
Country: PL	Rejestru Produktów Leczniczych	Identifier(s): 100449820
Country: US	FDA, National Drug Code	Identifier(s): 16110-391